Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Operating Leases (2022 - 2025)

Atea Pharmaceuticals' Operating Leases history spans 4 years, with the latest figure at $213000.0 for Q3 2025.

  • Quarterly Operating Leases fell 79.62% to $213000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $213000.0 through Sep 2025, down 79.62% year-over-year, with the annual reading at $842000.0 for FY2024, 48.72% down from the prior year.
  • Operating Leases came in at $213000.0 for Q3 2025, down from $425000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.8 million in Q2 2022 to a low of $213000.0 in Q3 2025.
  • The 4-year median for Operating Leases is $1.6 million (2023), against an average of $1.6 million.
  • Year-over-year, Operating Leases decreased 19.83% in 2023 and then crashed 79.62% in 2025.
  • Atea Pharmaceuticals' Operating Leases stood at $2.4 million in 2022, then tumbled by 31.67% to $1.6 million in 2023, then tumbled by 48.72% to $842000.0 in 2024, then tumbled by 74.7% to $213000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVIR's Operating Leases are $213000.0 (Q3 2025), $425000.0 (Q2 2025), and $634000.0 (Q1 2025).